B Biglari1, T Swing2, C Child2, A Büchler2, F Westhauser2, T Bruckner3, T Ferbert2, H Jürgen Gerner2, A Moghaddam2. 1. Department of Paraplegiolog, BG Trauma center Ludwigshafen, Ludwigshafen am Rhein, Germany. 2. Department of Orthopedics, Traumatology, and Paraplegiology, HTRG-Heidelberg Trauma Research Group, Trauma and Reconstructive Surgery, Heidelberg University Hospital, Heidelberg, Germany. 3. Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.
Abstract
STUDY DESIGN: Serum levels of interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) were measured over a 12-week period in 23 patients with spinal cord injury (SCI) with and without neurological improvement. OBJECTIVES: To determine the course of IL-1β and TNF-α in patients with SCI and observe a possible relationship between improvements in neurological functioning and cytokine levels. SETTING: All patients were treated at the BG Trauma Centre, Ludwigshafen, Germany. All lab work was done at the University Hospital, Heidelberg. METHODS: Spinal cord injury was classified according to the American Spinal Injury Association (ASIA) impairment scale (AIS) in 23 patients. TNF-α and IL-1β levels were measured upon arrival at the hospital, after 4 h, 9 h and 12 h, on days 1 and 3 and at the end of weeks 1, 2, 4, 8 and 12. RESULTS: Temporal changes in TNF-α and IL-1β in SCI patients were seen. Patients with AIS improvement (Group 1) had significantly lower TNF-α levels at 9 h compared with patients without AIS improvement (Group 2; P<0.01). The course of IL-1β fluctuated greatly between 4 h and week 1 in the groups; however, between 2 and 12 weeks post trauma, there was an overall decline in both groups. CONCLUSION: Measuring serum levels of TNF-α and IL-1β over time could be useful in tracking the course of SCI. Our data show differences in measured cytokines over a 12-week period for SCI patients with and without neurological improvement.
STUDY DESIGN: Serum levels of interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) were measured over a 12-week period in 23 patients with spinal cord injury (SCI) with and without neurological improvement. OBJECTIVES: To determine the course of IL-1β and TNF-α in patients with SCI and observe a possible relationship between improvements in neurological functioning and cytokine levels. SETTING: All patients were treated at the BG Trauma Centre, Ludwigshafen, Germany. All lab work was done at the University Hospital, Heidelberg. METHODS:Spinal cord injury was classified according to the American Spinal Injury Association (ASIA) impairment scale (AIS) in 23 patients. TNF-α and IL-1β levels were measured upon arrival at the hospital, after 4 h, 9 h and 12 h, on days 1 and 3 and at the end of weeks 1, 2, 4, 8 and 12. RESULTS: Temporal changes in TNF-α and IL-1β in SCI patients were seen. Patients with AIS improvement (Group 1) had significantly lower TNF-α levels at 9 h compared with patients without AIS improvement (Group 2; P<0.01). The course of IL-1β fluctuated greatly between 4 h and week 1 in the groups; however, between 2 and 12 weeks post trauma, there was an overall decline in both groups. CONCLUSION: Measuring serum levels of TNF-α and IL-1β over time could be useful in tracking the course of SCI. Our data show differences in measured cytokines over a 12-week period for SCI patients with and without neurological improvement.
Authors: K C Hayes; T C L Hull; G A Delaney; P J Potter; K A J Sequeira; K Campbell; P G Popovich Journal: J Neurotrauma Date: 2002-06 Impact factor: 5.269
Authors: Steven C Kirshblum; Stephen P Burns; Fin Biering-Sorensen; William Donovan; Daniel E Graves; Amitabh Jha; Mark Johansen; Linda Jones; Andrei Krassioukov; M J Mulcahey; Mary Schmidt-Read; William Waring Journal: J Spinal Cord Med Date: 2011-11 Impact factor: 1.985
Authors: Martina R Spiess; Roland M Müller; Rüdiger Rupp; Christian Schuld; Hubertus J A van Hedel Journal: J Neurotrauma Date: 2009-11 Impact factor: 5.269
Authors: Damien D Pearse; Francisco C Pereira; Alexander E Marcillo; Margaret L Bates; Yerko A Berrocal; Marie T Filbin; Mary Bartlett Bunge Journal: Nat Med Date: 2004-05-23 Impact factor: 53.440
Authors: B Biglari; A Büchler; T Swing; E Biehl; H J Roth; T Bruckner; G Schmidmaier; T Ferbert; H J Gerner; A Moghaddam Journal: Spinal Cord Date: 2012-11-27 Impact factor: 2.772
Authors: R A Heller; T F Raven; T Swing; K Kunzmann; V Daniel; P Haubruck; M Akbar; P A Grützner; G Schmidmaier; B Biglari; A Moghaddam Journal: Spinal Cord Date: 2017-06-20 Impact factor: 2.772
Authors: C H Hulme; S J Brown; H R Fuller; J Riddell; A Osman; J Chowdhury; N Kumar; W E Johnson; K T Wright Journal: Spinal Cord Date: 2016-12-20 Impact factor: 2.772
Authors: Arash Moghaddam; Christopher Child; Thomas Bruckner; Hans Jürgen Gerner; Volker Daniel; Bahram Biglari Journal: Int J Mol Sci Date: 2015-04-09 Impact factor: 5.923